2-gene panel for autosomal dominant polycystic kidney disease.
A focused 2-gene panel for autosomal dominant polycystic kidney disease (PKD1, PKD2) — the most common inherited kidney disease.
Bookable, after medical review.
Before the analysis, a specialist in human genetics reviews your preparation questionnaire and informs you (GenDG). If the test is declined, Atlas refunds the full amount.
You pay Atlas for Atlas Baseline and the analysis.
You receive a questionnaire by email from the physician's practice, and a specialist in human genetics reviews it. If the test is declined, you get a full automatic refund.
You choose a counselling slot or join the waitlist.
After the counselling you give your consent, then we ship your collection kit. The physician discusses the result with you.
Do you carry inherited variants that cause autosomal-dominant polycystic kidney disease?
Atlas analyzes each gene in its entirety -- not just hotspot regions -- against current clinical literature. Findings are assessed by a specialist in human genetics before release.
A focused 2-gene panel for autosomal dominant polycystic kidney disease (ADPKD) -- the most common inherited kidney disease. PKD1 variants typically present earlier and progress faster than PKD2.
Gene list version 2026-05.
Kidney disease is often discovered only when function is already impaired. ADPKD now has a disease-modifying therapy -- tolvaptan -- that can slow progression in selected patients. Early genetic diagnosis enables a nephrologist to begin imaging surveillance and consider therapy at the right time.
Every Atlas predictive report uses the same five-outcome framework so you and your physician can read it the same way each time.
Increased disease risk. The report includes an individualized prevention plan and a recommendation to discuss next steps with a physician or medical geneticist.
Probable disease association. Preventive monitoring is typically justified; the strength of evidence is documented in the report.
Reported but not currently actionable. A VUS may be reclassified over time as new evidence accumulates -- Atlas does not act on VUS findings without specialist review.
No pathogenic or likely-pathogenic variant was identified in the analyzed genes. This does not eliminate all genetic risk -- only the genes in this panel were assessed.
When an actionable variant is found, cascade testing of first-degree relatives is typically recommended -- a decision made together with a counselor.
Predictive genetic testing in Germany requires consultation with a physician qualified in human genetics under §7 of the GenDG (Arztvorbehalt). This counseling, before and after the test, is given by a specialist in human genetics. When an actionable finding has implications for relatives, this physician discusses cascade testing with you, not Atlas alone.
A variant indicates predisposition. It does not confirm a condition is currently present.
Imaging, lab work, and physical examination remain part of clinical care. Atlas results inform them; they do not substitute for them.
Environment, behavior, age, and chance contribute to most common conditions. A genetic test reads one input.
Only the genes on the panel were analyzed. Variants in other genes, in non-coding regions, and outside the assay's technical scope are not assessed.
Atlas reports are designed to be reviewed with a physician or medical geneticist. We do not recommend acting on a finding without that conversation.
GenDG §7
Predictive panels on this page are GenDG §7 Arztvorbehalt: counseling with a qualified human-genetics physician is required before and after the test. This counseling is given by a specialist in human genetics.
Ready to start?
Book →Not sure if this is the right protocol? Let Atlas walk you through a few questions. Start Triage →
Or browse all 24 protocols: Open the Console →
Not ready? Book a counseling session first →
Already have your genome with Atlas?
See Atlas Baseline